Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Thrombotic Risk and Its Management Across Diverse Clinical Settings
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Thrombotic Risk and Its Management Across Diverse Clinical Settings

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 458

Special Issue Editors

Dr. Samuel Bogdan Todor

E-Mail Website
Guest Editor
Faculty of Medicine, University Lucian Blaga of Sibiu, 550024 Sibiu, Romania
Interests: thrombosis; platelet activation; hypercoagulability; prothrombotic markers; endothelial dysfunction; inflammation; myeloproliferative neoplasms
Prof. Dr. Ana Maria Vlǎdǎreanu

E-Mail Website
Guest Editor
Department of Hematology, "Carol Davila" University of Medicine and Pharmacy, 030167 Bucharest, Romania
Interests: thrombosis; platelet activation; hypercoagulability; prothrombotic markers; endothelial dysfunction; inflammation; myeloproliferative neoplasms

Special Issue Information

Dear Colleagues,

Thrombosis remains a leading cause of morbidity and mortality across diverse patient populations, from those with hematologic malignancies and myeloproliferative neoplasms to those with cardiovascular disorders and autoimmune diseases. Despite advances in anticoagulation strategies, managing thrombotic risk remains challenging due to the complexity of underlying mechanisms and patient-specific factors. This Special Issue aims to advance knowledge on the molecular and clinical drivers of thrombosis, novel biomarkers for risk stratification, and personalized therapeutic approaches that balance thrombotic and bleeding risks. Core problems include gaps in predicting thrombotic events, the need for precision strategies in thromboprophylaxis, and evolving challenges such as cancer-associated and immune-mediated thrombosis.

We welcome research articles, reviews, and clinical studies exploring the pathophysiology of thrombosis, emerging diagnostic tools, and advancements in antithrombotic therapy. Authors are encouraged to address thrombotic risks in hematology, cardiovascular medicine, infectious diseases, and beyond. The issue seeks to mobilize a multidisciplinary community to provide comprehensive insights that improve patient outcomes.

Dr. Samuel Bogdan Todor
Prof. Dr. Ana Maria Vlǎdǎreanu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thrombosis
  • thrombotic risk
  • hematologic disorders
  • thrombophilia
  • myeloproliferative neoplasms
  • antithrombotic therapy
  • cardiovascular diseases
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 411 KB  
Article
Residual Vein Thrombosis After Deep Vein Thrombosis in Patients Treated with DOACs: Incidence and Associated Factors
by Marco Bardetta, Matteo Simoncini, Federica Valeri, Andrea Pizzuto, Cristina Dainese, Carola Sella, Annamaria Porreca, Benedetto Bruno and Alessandra Borchiellini
J. Clin. Med. 2025, 14(17), 5991; https://doi.org/10.3390/jcm14175991 - 25 Aug 2025
Viewed by 325
Abstract
Background/Objectives: After an initial course of anticoagulation for deep vein thrombosis (DVT), identifying patients at higher risk of recurrence remains a clinical challenge. The role of residual vein thrombosis (RVT) in this setting is still debated, as most available evidence derives from retrospective [...] Read more.
Background/Objectives: After an initial course of anticoagulation for deep vein thrombosis (DVT), identifying patients at higher risk of recurrence remains a clinical challenge. The role of residual vein thrombosis (RVT) in this setting is still debated, as most available evidence derives from retrospective studies or from the Warfarin era. We conducted a study to evaluate the incidence of RVT in patients treated with direct oral anticoagulants (DOACs) and to identify the clinical factors associated with its persistence. We also compared the outcomes from the two most prescribed drugs in Italy, Apixaban and Rivaroxaban. Methods: A total of 113 patients with newly diagnosed DVT underwent follow-up visits at 6 weeks (T1), 3 months (T2) and 6 months (T3) after diagnosis. RVT was assessed by compression ultrasonography and clinical, family and pathological history data were collected. Ninety-six patients were included in the final statistical analysis. Results: RVT was detected in 68.2%, 52.1% and 37.7% of patients at T1, T2 and T3, respectively. Factors significantly associated with RVT at T2 were male sex, femoral vein involvement and a family history of DVT. No significant differences were observed between Apixaban and Rivaroxaban. Prior episodes of thrombosis, smoking, diabetes and obesity were not associated with RVT at 3 months. Conclusions: Our findings confirm that RVT rates progressively decrease over time, as previously observed in the Coumarins era, but suggest a stronger early response to DOACs, particularly during the first three months of therapy. Moreover, DOACs appear to provide more effective protection in patients with risk factors for venous disease. Full article
(This article belongs to the Special Issue Thrombotic Risk and Its Management Across Diverse Clinical Settings)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop